Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Louis Legoux

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
JNCI Cancer Spectrum|September 29, 2023
Adjuvant chemotherapy benefit according to T and N stage in small bowel adenocarcinoma: a large retrospective multicenter studyAziz Zaanan, Julie Henriques, Anthony Turpin, et al.
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|February 13, 2021
Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk Stage II and III colon cancers? Three years' follow-up results of the PRODIGE 22 phase II randomized multicentre trialMehdi Karoui, Claire Gallois, Guillaume Piessen, et al.
International Journal of Cancer|November 13, 2020
Panel gene profiling of small bowel adenocarcinoma: Results from the NADEGE prospective cohortThomas Aparicio, Magali Svrcek, Julie Henriques, et al.
European Journal of Cancer (Oxford, England : 1990)|September 10, 2022
Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD studyCôme Lepage, Jean-Marc Phelip, Astrid Lievre, et al.
European Journal of Cancer (Oxford, England : 1990)|May 29, 2018
Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trialsThomas Aparicio, Michel Ducreux, Roger Faroux, et al.
International Journal of Cancer|January 9, 2020
Small bowel adenocarcinoma: Results from a nationwide prospective ARCAD-NADEGE cohort study of 347 patientsThomas Aparicio, Julie Henriques, Sylvain Manfredi, et al.
Plos One|August 27, 2015
FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated PatientsCindy Serdjebi, Johan Gagnière, Jérôme Desramé, et al.
Cancers|June 4, 2020
Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal CarcinomaJulie Niogret, Emeric Limagne, Marion Thibaudin, et al.
Bulletin Du Cancer|June 30, 2019
[Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists]Marie-Anne Loriot, Fadil Masskouri, Paolo Carni, et al.
Journal of Hepatology|May 25, 2019
Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinomaJean-Louis Jouve, Thierry Lecomte, Olivier Bouché, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
JNCI Cancer Spectrum|September 29, 2023
Adjuvant chemotherapy benefit according to T and N stage in small bowel adenocarcinoma: a large retrospective multicenter studyAziz Zaanan, Julie Henriques, Anthony Turpin, et al.
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|February 13, 2021
Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk Stage II and III colon cancers? Three years' follow-up results of the PRODIGE 22 phase II randomized multicentre trialMehdi Karoui, Claire Gallois, Guillaume Piessen, et al.
International Journal of Cancer|November 13, 2020
Panel gene profiling of small bowel adenocarcinoma: Results from the NADEGE prospective cohortThomas Aparicio, Magali Svrcek, Julie Henriques, et al.
European Journal of Cancer (Oxford, England : 1990)|September 10, 2022
Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD studyCôme Lepage, Jean-Marc Phelip, Astrid Lievre, et al.
European Journal of Cancer (Oxford, England : 1990)|May 29, 2018
Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trialsThomas Aparicio, Michel Ducreux, Roger Faroux, et al.
International Journal of Cancer|January 9, 2020
Small bowel adenocarcinoma: Results from a nationwide prospective ARCAD-NADEGE cohort study of 347 patientsThomas Aparicio, Julie Henriques, Sylvain Manfredi, et al.
Plos One|August 27, 2015
FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated PatientsCindy Serdjebi, Johan Gagnière, Jérôme Desramé, et al.
Cancers|June 4, 2020
Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal CarcinomaJulie Niogret, Emeric Limagne, Marion Thibaudin, et al.
Bulletin Du Cancer|June 30, 2019
[Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists]Marie-Anne Loriot, Fadil Masskouri, Paolo Carni, et al.
Journal of Hepatology|May 25, 2019
Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinomaJean-Louis Jouve, Thierry Lecomte, Olivier Bouché, et al.
Pageof 4